Browse studies
Find your next paid study
2 recruiting studies matching your filters
Phase 1
A Phase 1B/2 Pan-Tumor, Open-Label Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck …
Recurrent or Metastatic Solid Tumors
Estimated
~$10 – $7,500
Daiichi SankyoNCT06330064
Phase 1
A Phase 1, Multicenter Trial of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors
This dose escalation and dose expansion study was designed to assess the safety, tolerability, PK and efficacy of subcutaneous T-DXd in participants with metas…
Recurrent or Metastatic Solid Tumors
Estimated
~$10 – $7,500
Daiichi SankyoNCT07015697